150/25/1 mg tablets, Scored tablet · Dog 1.25–2 kg Dog 1.25–2 kg 1/4 tablet Do not use below 1.25 kg, under 8 weeks, in pregnancy/lactation, with emaciation, infection, epilepsy, hyperthermia, liver/kidney dysfunction, MDR1/macrolactone sensitivity, within 6 weeks of another macrocyclic lactone, or with cholinesterase inhibitors/piperazine. Adverse effects can include salivation, vomiting, diarrhoea, anorexia, depression, ataxia, tremor, mydriasis, excitability and photophobia; convulsions are very rare.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 20 May 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000608
Verified on: 21 Oct 2026
150/25/1 mg tablets, Scored tablet · Dog 2.1–3 kg Dog 2.1–3 kg 1/2 tablet Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 20 May 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000608
Verified on: 21 Oct 2026
150/25/1 mg tablets, Scored tablet · Dog 4–5 kg Dog 4–5 kg 1 tablet Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 20 May 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000608
Verified on: 21 Oct 2026
150/25/1 mg tablets, Scored tablet · Dog 6–8 kg Dog 6–8 kg 1 1/2 tablets Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 20 May 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000608
Verified on: 21 Oct 2026
150/25/1 mg tablets, Scored tablet · Dog 9–10 kg Dog 9–10 kg 2 tablets This strength is an official alternative at 9-10 kg; use the pack prescribed for the patient. Follow all label precautions.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 20 May 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000608
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration
OKVET ExpressTabs 150/25/1 mg tablets, Scored tablet
N2 for dogs up to 5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Weak evidence support
Details →
vetman assessment
OKVET ExpressTabs
×
150/25/1 mg tablets, N2 for dogs up to 5 kg
Assessed clinical scope Dog · Full labelled canine oral scope in an explicitly printed weight-table cell: treatment and control of susceptible fleas, ticks, lice, mites, gastrointestinal nematodes and cestodes, and prevention of susceptible Dirofilaria larval infection · By mouth
Care setting Veterinary-selected home dosing with parasite and heartworm-risk assessment, exact table-cell selection, administration with or immediately after food and follow-up appropriate to the target parasite
vetman score
6.0/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, veterinary · № 000608 · Verified on 21 Oct 2026
A locally registered, broad-spectrum dog tablet with exact-product evidence and relatively flexible small-dog dosing. It remains a weak-to-situational choice because evidence is mostly sponsor-linked and safety restrictions are substantial; use only an explicit weight-table cell and diagnose the target parasite.
Regulatory and scientific credibility 6.5/10
The exact strengths are actively registered in Georgia, a regulator-hosted Moldovan leaflet independently corroborates identity and use, and multiple exact-product studies are published. However, no EMA/FDA-style public assessment or transparent full dossier was found, and much of the evidence is manufacturer-linked.
Clinical efficacy 6.0/10
Exact-product studies report high efficacy against selected naturally or experimentally infested ectoparasites and provide pharmacokinetic support for all three actives. Study groups are generally small, comparator, blinding and sponsor independence are limited, and the very broad label spectrum and every claimed duration are not validated equally well.
Safety and tolerability 4.5/10
A 30-dog tolerance study found no important effect at the therapeutic regimen, but five consecutive daily double doses caused salivation, vomiting, incoordination, depression or mydriasis in 30% of dogs. The exact label has extensive age, reproductive, disease, MDR1/macrolactone and drug-combination restrictions; uncommon-event and diverse-patient safety remain incompletely defined.
Clinical practicality 7.5/10
Quarter-tablet scoring and explicit small-dog cells make this the most flexible presentation. It must still be given with or just after food and only for printed weight cells; the table contains gaps and alternative-strength overlaps that must not be interpolated.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not use below 1.25 kg, under 8 weeks of age, during pregnancy or lactation, or in emaciated, infectious-disease, hyperthermic, hepatic, renal or epileptic patients. Avoid in known MDR1/ABCB1 or macrocyclic-lactone sensitivity unless a specialist has explicitly assessed the individual risk. Do not use within 6 weeks of another macrocyclic lactone and do not combine with cholinesterase inhibitors or piperazine. Review every antiparasitic active ingredient before dosing. Give with a small amount of food or immediately after feeding. If vomiting occurs soon after dosing, do not automatically repeat the dose; assess timing, visible tablet loss and patient risk with a veterinarian. Monitor for anorexia, vomiting, diarrhoea, salivation, ataxia, depression, mydriasis, tremor, excitation, photophobia or convulsions. A repeated double-dose tolerance study produced poisoning signs in 30% of dogs. Use only an explicitly printed weight-table cell. The official table contains gaps and overlapping alternative strengths; do not interpolate a missing band or convert the combination into a continuous mg/kg rule. Heartworm use is prevention against susceptible larval stages, not treatment of adult infection. Assess geographic exposure, test as clinically indicated and follow current canine heartworm guidance. The broad label does not mean every parasite is present or equally supported by evidence. Identify the likely parasite, use appropriate diagnostics and confirm response or clearance where the disease requires it. Most exact-product studies are small and manufacturer-linked. Their positive findings do not replace independent surveillance, transparent regulator assessment or reassessment when expected control fails. Prevent access by cats, children and unintended dogs, record the date and exact strength, and avoid accidental repeat dosing across household parasite-control products. Assessment sources +
Close
Administration route
By mouth
Manufacturer (register)
AVZ S-P Ltd, Russia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1087, 19 Oct 2026.
Registration
Georgia
Yes, veterinary
In force until 20 May 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000608
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
Dose Species Weight Route Frequency Source
1/4 tablet
Do not use below 1.25 kg, under 8 weeks, in pregnancy/lactation, with emaciation, infection, epilepsy, hyperthermia, liver/kidney dysfunction, MDR1/macrolactone sensitivity, within 6 weeks of another macrocyclic lactone, or with cholinesterase inhibitors/piperazine. Adverse effects can include salivation, vomiting, diarrhoea, anorexia, depression, ataxia, tremor, mydriasis, excitability and photophobia; convulsions are very rare.
Dog
1.25–2 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
1/2 tablet
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
2.1–3 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
1 tablet
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
4–5 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
1 1/2 tablets
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
6–8 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
2 tablets
This strength is an official alternative at 9-10 kg; use the pack prescribed for the patient. Follow all label precautions.
Dog
9–10 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
300/50/2 mg tablets, Scored tablet · Dog 4–5 kg Dog 4–5 kg 1/2 tablet Do not use below 1.25 kg, under 8 weeks, in pregnancy/lactation, with emaciation, infection, epilepsy, hyperthermia, liver/kidney dysfunction, MDR1/macrolactone sensitivity, within 6 weeks of another macrocyclic lactone, or with cholinesterase inhibitors/piperazine. Monitor for the adverse effects listed in the label.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 03 Jun 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000624
Verified on: 21 Oct 2026
300/50/2 mg tablets, Scored tablet · Dog 6–8 kg Dog 6–8 kg 3/4 tablet Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 03 Jun 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000624
Verified on: 21 Oct 2026
300/50/2 mg tablets, Scored tablet · Dog 9–10 kg Dog 9–10 kg 1 tablet Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 03 Jun 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000624
Verified on: 21 Oct 2026
300/50/2 mg tablets, Scored tablet · Dog 11–14 kg Dog 11–14 kg 1 1/4 tablets Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 03 Jun 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000624
Verified on: 21 Oct 2026
300/50/2 mg tablets, Scored tablet · Dog 15 kg Dog 15 kg 1 1/2 tablets Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 03 Jun 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000624
Verified on: 21 Oct 2026
300/50/2 mg tablets, Scored tablet · Dog 16–20 kg Dog 16–20 kg 2 tablets Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 03 Jun 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000624
Verified on: 21 Oct 2026
300/50/2 mg tablets, Scored tablet · Dog 21–25 kg Dog 21–25 kg 2 1/2 tablets This is an explicit official-table cell; do not substitute the 900 mg tablet because its 21-25 kg cell is blank.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 03 Jun 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000624
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration
OKVET ExpressTabs 300/50/2 mg tablets, Scored tablet
N3 for dogs 5-15 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Weak evidence support
Details →
vetman assessment
OKVET ExpressTabs
×
300/50/2 mg tablets, N3 for dogs 5-15 kg
Assessed clinical scope Dog · Full labelled canine oral scope in an explicitly printed weight-table cell: treatment and control of susceptible fleas, ticks, lice, mites, gastrointestinal nematodes and cestodes, and prevention of susceptible Dirofilaria larval infection · By mouth
Care setting Veterinary-selected home dosing with parasite and heartworm-risk assessment, exact table-cell selection, administration with or immediately after food and follow-up appropriate to the target parasite
vetman score
5.9/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, veterinary · № 000624 · Verified on 21 Oct 2026
A locally registered broad-spectrum option with exact-product studies, but evidence independence and broad-claim coverage are limited. Its discontinuous dosing table and substantial safety restrictions require deliberate veterinary selection rather than a generic monthly all-parasite assumption.
Regulatory and scientific credibility 6.5/10
The exact strengths are actively registered in Georgia, a regulator-hosted Moldovan leaflet independently corroborates identity and use, and multiple exact-product studies are published. However, no EMA/FDA-style public assessment or transparent full dossier was found, and much of the evidence is manufacturer-linked.
Clinical efficacy 6.0/10
Exact-product studies report high efficacy against selected naturally or experimentally infested ectoparasites and provide pharmacokinetic support for all three actives. Study groups are generally small, comparator, blinding and sponsor independence are limited, and the very broad label spectrum and every claimed duration are not validated equally well.
Safety and tolerability 4.5/10
A 30-dog tolerance study found no important effect at the therapeutic regimen, but five consecutive daily double doses caused salivation, vomiting, incoordination, depression or mydriasis in 30% of dogs. The exact label has extensive age, reproductive, disease, MDR1/macrolactone and drug-combination restrictions; uncommon-event and diverse-patient safety remain incompletely defined.
Clinical practicality 7.0/10
Quarter-tablet scoring provides useful flexibility across several explicit cells, but the official table is discontinuous and extends this presentation beyond its marketing subtitle. Select the printed cell rather than inferring a continuous mg/kg rule or substituting another strength.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not use below 1.25 kg, under 8 weeks of age, during pregnancy or lactation, or in emaciated, infectious-disease, hyperthermic, hepatic, renal or epileptic patients. Avoid in known MDR1/ABCB1 or macrocyclic-lactone sensitivity unless a specialist has explicitly assessed the individual risk. Do not use within 6 weeks of another macrocyclic lactone and do not combine with cholinesterase inhibitors or piperazine. Review every antiparasitic active ingredient before dosing. Give with a small amount of food or immediately after feeding. If vomiting occurs soon after dosing, do not automatically repeat the dose; assess timing, visible tablet loss and patient risk with a veterinarian. Monitor for anorexia, vomiting, diarrhoea, salivation, ataxia, depression, mydriasis, tremor, excitation, photophobia or convulsions. A repeated double-dose tolerance study produced poisoning signs in 30% of dogs. Use only an explicitly printed weight-table cell. The official table contains gaps and overlapping alternative strengths; do not interpolate a missing band or convert the combination into a continuous mg/kg rule. Heartworm use is prevention against susceptible larval stages, not treatment of adult infection. Assess geographic exposure, test as clinically indicated and follow current canine heartworm guidance. The broad label does not mean every parasite is present or equally supported by evidence. Identify the likely parasite, use appropriate diagnostics and confirm response or clearance where the disease requires it. Most exact-product studies are small and manufacturer-linked. Their positive findings do not replace independent surveillance, transparent regulator assessment or reassessment when expected control fails. Prevent access by cats, children and unintended dogs, record the date and exact strength, and avoid accidental repeat dosing across household parasite-control products. Assessment sources +
Close
Administration route
By mouth
Manufacturer (register)
AVZ S-P Ltd, Russia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1111, 19 Oct 2026.
Registration
Georgia
Yes, veterinary
In force until 03 Jun 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000624
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
Dose Species Weight Route Frequency Source
1/2 tablet
Do not use below 1.25 kg, under 8 weeks, in pregnancy/lactation, with emaciation, infection, epilepsy, hyperthermia, liver/kidney dysfunction, MDR1/macrolactone sensitivity, within 6 weeks of another macrocyclic lactone, or with cholinesterase inhibitors/piperazine. Monitor for the adverse effects listed in the label.
Dog
4–5 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
3/4 tablet
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
6–8 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
1 tablet
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
9–10 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
1 1/4 tablets
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
11–14 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
1 1/2 tablets
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
15 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
2 tablets
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
16–20 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
2 1/2 tablets
This is an explicit official-table cell; do not substitute the 900 mg tablet because its 21-25 kg cell is blank.
Dog
21–25 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
900/150/6 mg tablets, Scored tablet · Dog 15 kg Dog 15 kg 1/2 tablet Do not use below 1.25 kg, under 8 weeks, in pregnancy/lactation, with emaciation, infection, epilepsy, hyperthermia, liver/kidney dysfunction, MDR1/macrolactone sensitivity, within 6 weeks of another macrocyclic lactone, or with cholinesterase inhibitors/piperazine. Monitor for the adverse effects listed in the label.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 25 Apr 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000599 | 000640
Verified on: 21 Oct 2026
900/150/6 mg tablets, Scored tablet · Dog 16–20 kg Dog 16–20 kg 3/4 tablet Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 25 Apr 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000599 | 000640
Verified on: 21 Oct 2026
900/150/6 mg tablets, Scored tablet · Dog 26–30 kg Dog 26–30 kg 1 tablet The official table has no 21-25 kg cell for this strength. Do not interpolate the omitted band.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 25 Apr 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000599 | 000640
Verified on: 21 Oct 2026
900/150/6 mg tablets, Scored tablet · Dog 31–40 kg Dog 31–40 kg 1 1/4 tablets Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 25 Apr 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000599 | 000640
Verified on: 21 Oct 2026
900/150/6 mg tablets, Scored tablet · Dog 41–45 kg Dog 41–45 kg 1 1/2 tablets Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 25 Apr 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000599 | 000640
Verified on: 21 Oct 2026
900/150/6 mg tablets, Scored tablet · Dog 46–60 kg Dog 46–60 kg 2 tablets Above 60 kg the label requires a combination of strengths selected by body weight; this single-presentation table does not invent that combination.
· once with or immediately after food once with or immediately after food
Georgia
Yes, veterinary
In force until 25 Apr 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000599 | 000640
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration
OKVET ExpressTabs 900/150/6 mg tablets, Scored tablet
N2 for dogs 15-60 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Weak evidence support
Details →
vetman assessment
OKVET ExpressTabs
×
900/150/6 mg tablets, N2 for dogs 15-60 kg
Assessed clinical scope Dog · Full labelled canine oral scope in an explicitly printed weight-table cell: treatment and control of susceptible fleas, ticks, lice, mites, gastrointestinal nematodes and cestodes, and prevention of susceptible Dirofilaria larval infection · By mouth
Care setting Veterinary-selected home dosing with parasite and heartworm-risk assessment, exact table-cell selection, administration with or immediately after food and follow-up appropriate to the target parasite
vetman score
5.7/10
Weak evidence support
Evidence confidence: Medium
Georgia: Yes, veterinary · № 000599 | 000640 · Verified on 21 Oct 2026
A locally registered broad-spectrum option with exact-product studies, but the large-dog presentation has material table gaps and combination requirements, while safety and evidence limitations remain. Use only the explicit cell selected for the dog and do not interpolate missing bands.
Regulatory and scientific credibility 6.5/10
The exact strengths are actively registered in Georgia, a regulator-hosted Moldovan leaflet independently corroborates identity and use, and multiple exact-product studies are published. However, no EMA/FDA-style public assessment or transparent full dossier was found, and much of the evidence is manufacturer-linked.
Clinical efficacy 6.0/10
Exact-product studies report high efficacy against selected naturally or experimentally infested ectoparasites and provide pharmacokinetic support for all three actives. Study groups are generally small, comparator, blinding and sponsor independence are limited, and the very broad label spectrum and every claimed duration are not validated equally well.
Safety and tolerability 4.5/10
A 30-dog tolerance study found no important effect at the therapeutic regimen, but five consecutive daily double doses caused salivation, vomiting, incoordination, depression or mydriasis in 30% of dogs. The exact label has extensive age, reproductive, disease, MDR1/macrolactone and drug-combination restrictions; uncommon-event and diverse-patient safety remain incompletely defined.
Clinical practicality 6.0/10
Oral dosing and quarter-tablet scoring are convenient, but the large-dog table has no 21-25 kg cell for this strength and requires another strength there; above 60 kg the label uses combinations not supplied by this single presentation. These gaps materially increase selection and pack-management burden.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not use below 1.25 kg, under 8 weeks of age, during pregnancy or lactation, or in emaciated, infectious-disease, hyperthermic, hepatic, renal or epileptic patients. Avoid in known MDR1/ABCB1 or macrocyclic-lactone sensitivity unless a specialist has explicitly assessed the individual risk. Do not use within 6 weeks of another macrocyclic lactone and do not combine with cholinesterase inhibitors or piperazine. Review every antiparasitic active ingredient before dosing. Give with a small amount of food or immediately after feeding. If vomiting occurs soon after dosing, do not automatically repeat the dose; assess timing, visible tablet loss and patient risk with a veterinarian. Monitor for anorexia, vomiting, diarrhoea, salivation, ataxia, depression, mydriasis, tremor, excitation, photophobia or convulsions. A repeated double-dose tolerance study produced poisoning signs in 30% of dogs. Use only an explicitly printed cell. This strength has no 21-25 kg cell; use the labelled alternative strength there. Above 60 kg, follow a veterinarian-selected labelled combination and do not invent a single-strength dose. Heartworm use is prevention against susceptible larval stages, not treatment of adult infection. Assess geographic exposure, test as clinically indicated and follow current canine heartworm guidance. The broad label does not mean every parasite is present or equally supported by evidence. Identify the likely parasite, use appropriate diagnostics and confirm response or clearance where the disease requires it. Most exact-product studies are small and manufacturer-linked. Their positive findings do not replace independent surveillance, transparent regulator assessment or reassessment when expected control fails. Prevent access by cats, children and unintended dogs, record the date and exact strength, and avoid accidental repeat dosing across household parasite-control products. Assessment sources +
Close
Administration route
By mouth
Registration
Georgia
Yes, veterinary
In force until 25 Apr 2029
Veterinary (National Food Agency)
In the register: ექსპრესტაბსი®
№ 000599 | 000640
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
Dose Species Weight Route Frequency Source
1/2 tablet
Do not use below 1.25 kg, under 8 weeks, in pregnancy/lactation, with emaciation, infection, epilepsy, hyperthermia, liver/kidney dysfunction, MDR1/macrolactone sensitivity, within 6 weeks of another macrocyclic lactone, or with cholinesterase inhibitors/piperazine. Monitor for the adverse effects listed in the label.
Dog
15 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
3/4 tablet
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
16–20 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
1 tablet
The official table has no 21-25 kg cell for this strength. Do not interpolate the omitted band.
Dog
26–30 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
1 1/4 tablets
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
31–40 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
1 1/2 tablets
Follow the same contraindications, interaction restrictions and adverse-effect monitoring stated for this product.
Dog
41–45 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
2 tablets
Above 60 kg the label requires a combination of strengths selected by body weight; this single-presentation table does not invent that combination.
Dog
46–60 kg
By mouth
once with or immediately after food
ExpressTabs label
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
OKVET ExpressTabs tablets - official veterinary instruction
AVZ official veterinary product information, 2026
